Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05141682 · ClinicalTrials.gov registry record · Phase 1
Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia
A Phase 1 study of T-cell Large Granular Lymphocyte Leukemia, sponsored by Jonathan Brammer.
- Active
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 2
- Study locations
NCT05141682 is a Phase 1 study of T-cell Large Granular Lymphocyte Leukemia that is active but no longer recruiting, run by Jonathan Brammer. The registered enrollment target is 11 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT05141682, a Phase 1 study of T-cell Large Granular Lymphocyte Leukemia, is active but no longer recruiting, sponsored by Jonathan Brammer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I/II trial studies the best dose, possible benefits and/or side effects of oral azacitidine in treating patients with T-cell large granular lymphocytic leukemia that has come back (relapsed) or has not responded to previous treatment (refractory). Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Conditions Studied
Interventions
- DRUG Oral Azacitidine
Study Locations (2)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2022-06-29 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05141682
The ClinicalTrials.gov registry entry for NCT05141682 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonathan Brammer, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with T-cell Large Granular Lymphocyte Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Oral Azacitidine is the first listed.
NCT05141682 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Virginia.
Frequently Asked Questions
What is clinical trial NCT05141682 about?
NCT05141682 is a clinical study titled "Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia". This phase I/II trial studies the best dose, possible benefits and/or side effects of oral azacitidine in treating patients with T-cell large granular lymphocytic leukemia that has come back (relapsed) or has not responded to previous treatment (refractory). Chemotherapy drugs, such as azacitidine, ...
What is the current status of trial NCT05141682?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2022-06-29. Estimated completion is 2026-06-30.
What conditions does trial NCT05141682 study?
This clinical trial studies the following conditions: T-cell Large Granular Lymphocyte Leukemia.
What interventions are being tested in trial NCT05141682?
The interventions under investigation include: Oral Azacitidine (DRUG).
Who is sponsoring clinical trial NCT05141682?
This trial is sponsored by Jonathan Brammer, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05141682 being conducted?
This trial has 2 study locations across Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for T-cell Large Granular Lymphocyte Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.